CLASS II Drug recall · Reported 23 Dec 2020 · FDA Enforcement Report

Azacitidine for Injection 100 mg/vial For Subcutaneous recalled by CIPLA

CIPLA is recalling Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only, distributed nationwide in the US. The recall was initiated on 14 Dec 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 7S10182A, Ex 9/2021
Quantity recalled2151 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0165-2021
FDA event ID
86969
Recalling firm
CIPLA, Warren, NJ
Classification
Class II
Status
Terminated
Recall initiated
14 Dec 2020
FDA classified
16 Dec 2020
Reported
23 Dec 2020
Type
Voluntary: Firm initiated
Customers notified by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Reason category
Sterility

Timeline

14 Dec 2020Recall initiated by company
16 Dec 2020Classified by FDA+2 days
23 Dec 2020Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

cGMP deviations: Vials may not be sealed correctly affecting sterility.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40

Where it was distributed

USA Nationwide

Nationwide

Questions about this recall

Is Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only recalled?

Yes. CIPLA recalled Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only on 14 Dec 2020. The recall is Class II and its status is Terminated. Recall number D-0165-2021.

Why was it recalled?

cGMP deviations: Vials may not be sealed correctly affecting sterility.

Which lots are affected?

Lot #: 7S10182A, Ex 9/2021

Where was it sold?

USA Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from CIPLA

All 14
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIPhytonadione Injectable Emulsion, USP 10mg/mL recalled by CiplaPhytonadioneCiplaPotency & AssayNationwide
DrugCLASS IIArformoterol Tartrate Inhalation Solution recalled by CIPLAArformoterol TartrateCIPLASterilityNationwide
DrugCLASS IIBudesonide Inhalation Suspension 25mg/, For Inhalation Only recalledBudesonideCIPLASterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLADifluprednateCIPLASterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLACIPLASterilityNationwide

Other Azacitidine recalls

All 8